India’s Pharma Industry Faces Fresh Challenges After Trump’s Drug Order
In a significant shift that could disrupt global pharmaceutical pricing, US President Donald Trump has announced a “Most Favoured Nation” (MFN) executive order aiming to ensure that Americans pay no more for prescription drugs than the lowest price paid globally. This move is expected to benefit American consumers in the short term but may lead to rising prices in low-cost markets like India and pressure on its domestic pharmaceutical policy.
The MFN policy announced by Trump on May 12, 2025, could lead to a recalibration of drug prices worldwide. As global pharma companies aim to align drug pricing across countries, India—known for its affordable generics—could be pushed to hike prices. The development has already caused turmoil in Indian pharmaceutical stocks over margin concerns.
| Summary/Static | Details |
| Why in the news? | India’s Pharma Industry Faces Fresh Challenges After Trump’s Drug Order |
| Policy Introduced | Most Favoured Nation (MFN) Pricing Order by US President Donald Trump |
| Goal Align | US drug prices with the lowest global prices |
| Potential Impact on India | Pressure to increase drug prices and alter IP laws |
| Beneficiaries | US consumers (short-term) |
| Risk Areas | Pharma company margins, especially distributors; potential FTAs impact |
| Industry Opinion | (India) Cost burden lies more on supply chain than manufacturers |
Dr Colleen Begg from South Africa has won the 2026 Prince William Award for Conservation…
Professor Shekhar C. Mande, President of the Indian National Science Academy (INSA), has been appointed…
The winners of the National Gopal Ratna Awards (NGRA) 2026 have been announced. It aims…
Four cheetah cubs have been born to a female cheetah in the wild, increasing the…
India has developed its very own H5N1 subtype Bird Flu Vaccine for Chickens. On November…
On 20 th November 2026, the Prime Minister Narendra Modi formally opened the First Shanghai…